


Claims


1. A compound of formula (I):



5

wherein:

One of **R¹** and **R²** is selected from a group (IA):



(IA)

- 10 and the other **R¹** or **R²** is selected from hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, carbocyclyl, heterocyclyl, carbocyclyloxy and heterocyclyloxy; wherein this **R¹** or **R²** may be optionally substituted on carbon by one or more groups selected from **R⁵**; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by C₁₋₄alkyl;
- 15 Ring **A** is pyridin-2-yl or thiazol-2-yl; wherein said pyridin-2-yl or thiazol-2-yl may be optionally substituted on carbon by one or more groups selected from **R⁶**; one of **R³** and **R⁴** is hydrogen and the other is selected from hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, carbocyclyl, heterocyclyl, carbocyclyloxy and heterocyclyloxy; wherein **R³** and **R⁴** may be independently optionally substituted on carbon by one or more groups selected from **R⁷**; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by C₁₋₄alkyl;
- 20 **R⁶** is selected from halo, carboxy and C₁₋₄alkyl;
- R⁵** and **R⁷** are independently selected from halo, C₁₋₄alkyl, C₁₋₄alkoxy, N-(C₁₋₄alkyl)amino, N,N-(C₁₋₄alkyl)₂amino, carbocyclyl, heterocyclyl, carbocyclyloxy, heterocyclyloxy and carbocyclidenyl; wherein **R⁵** and **R⁷** may be independently optionally substituted on carbon by one or more **R⁸**; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by C₁₋₄alkyl;
- 25

- 33 -


\mathbf{R}^8 is selected from halo, carboxy, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino and *N*-methyl-*N*-ethylamino; or a salt, solvate or pro-drug thereof.

- 5 2. A compound according to Claim 1 wherein one of \mathbf{R}^1 and \mathbf{R}^2 is selected from a group (IA) and the other \mathbf{R}^1 or \mathbf{R}^2 is selected from C₁₋₄alkoxy; wherein this \mathbf{R}^1 or \mathbf{R}^2 may be optionally substituted on carbon by one or more groups selected from \mathbf{R}^5 .
- 10 3. A compounds according to Claim 2 wherein Ring A in the group (IA) is substituted by carboxy and the C₁₋₄alkoxy group is substituted on carbon by one or more groups selected from \mathbf{R}^5 .
- 15 4. A compound according to Claim 3 wherein \mathbf{R}^5 is selected from carbocyclyl optionally substituted by one or more \mathbf{R}^8 .
5. A compound according to any one of the preceding claims wherein one of \mathbf{R}^3 and \mathbf{R}^4 is hydrogen and the other is C₁₋₄alkyl.
- 20 6. A compound according to Claim 1 selected from:
2-(2-Chlorobenzylxy)-4-[*N*-(5-carboxythiazol-2-yl)carbamoyl]-6-methylquinoline;
2-(2-Chlorobenzylxy)-4-[*N*-(5-carboxythiazol-2-yl)carbamoyl]-quinoline;
2-(2-Chlorobenzylxy)-4-[*N*-(5-carboxypyrid-2-yl)carbamoyl]-6-methylquinoline;
2-(2-Chlorobenzylxy)-4-[*N*-(5-carboxypyrid-2-yl)carbamoyl]-quinoline;
2-[*N*-(5-carboxypyrid-2-yl)carbamoyl]-4-(2-methylbenzylxy)-quinoline; and
25 2-(1-methylpropoxy)-4-[*N*-(5-carboxythiazol-2-yl)carbamoyl]-quinoline;
or a salt, solvate or pro-drug thereof.
7. A pharmaceutical composition comprising a compound according to any one of Claims 1 to 6, or a salt, pro-drug or solvate thereof, together with a pharmaceutically acceptable diluent or carrier.
- 30 8. A compound according to any one of Claims 1 to 6 for use in the preparation of a medicament for treatment of a disease mediated through GLK.


- 34 -

9. A process for preparing a compound according to Claim 1, or a salt, solvate or pro-drug thereof, which process (wherein variable groups are, unless otherwise specified, as defined in Claim 1) comprises:

5 *Process 1):* reacting an acid of formula (IIa) or (IIb):




(IIa)



(IIb)

or an activated derivative thereof; with a compound of formula (III)




10


(III);

or

Process 2) for compounds of formula (I) wherein R⁶ is carboxy; deprotecting a compound of formula (IIIa) or (IIIb):



(IIIa)



(IIIb)

15

wherein R^xC(O)O- is an ester group;

and thereafter if necessary or desirable:

- i) converting a compound of the formula (I) into another compound of the formula (I); and/or
- ii) removing any protecting groups; and/or

- 35 -

- iii) forming a salt, solvate or pro-drug thereof.
10. A compound of formula (IIIa) or a compound of formula (IIIb) as defined in Claim 9.